Leadership Team

David Meeker, MD, Chief Executive Officer

Dr. Meeker is the President & CEO of KSQ, a biotech company with a proprietary CRISPRomics drug discovery engine. Utilizing this engine, KSQ is advancing a pipeline of oncology and immuno-oncology drug development programs. Dr. Meeker was formerly the President and CEO of Genzyme, a Sanofi company, a position he assumed when Genzyme merged with Sanofi in 2011. He was also a member of the executive committee.

In his career with Genzyme, Dr. Meeker held key positions of increasing responsibility beginning in the R&D organization and subsequently in operating roles, culminating in the position of Chief Operating Officer at the time of the merger. In his most recent role within Sanofi, he headed Sanofi-Genzyme, the specialty care unit with responsibility for Rare Diseases, MS, Oncology and Immunology franchises.

Prior to joining Genzyme, Dr. Meeker was the Director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic and an assistant professor of medicine at Ohio State University. He completed his internal medicine training at Harvard’s Beth Israel Hospital and his pulmonary/critical training at Boston University. He completed the Advanced Management Program at Harvard Business School in 2000.

Dr. Meeker is the Chairman of the Board of Rhythm Pharmaceuticals, and Trevi Therapeutics and a member of the board at Myokardia. He also serves on the boards of the Biomedical Science Careers Program, the Network for Excellence in Health Innovation and the Dimock Center, a Boston based community health center.

Micah Benson, PhD, Head of Immunobiology

Micah Benson has more than 15 years of industry and academic experience as an expert immunologist and drug hunter.  Prior to joining KSQ Therapeutics, Micah served as Head of Tolerance Therapeutics in the Immunology and Inflammation Research Unit at Pfizer, Inc.  In this capacity, Micah was responsible for building and overseeing a drug discovery portfolio and identifying and seeding external research opportunities with biopharma partners focused on immune tolerance induction technologies.  This included leading innovative approaches encompassing biologic, targeted drug delivery and cell therapy modalities, and working with patient advocacy groups to seed new opportunities in the immune tolerance space.  He earned his PhD in Immunology from Dartmouth Medical School in Dr. Randy Noelle’s lab, where he discovered factors driving T regulatory cell differentiation, and was a Leukemia Lymphoma Society postdoctoral fellow at Harvard Medical School in Anjana Rao’s lab, where he worked on mRNA splicing factors in B lymphocytes.  He has authored several patents and published extensively in top-tier scientific journals.


Caroline Dugopolski, Vice President, Technical Operations

Caroline Dugopolski is a technical operations leader with more than 18 years of industry experience in GMP clinical and commercial manufacturing operations across biologic, device, and cell therapy products. Prior to joining KSQ, Caroline spent five years leading technical operations functions at Histogenics Corporation, including manufacturing, quality control, and analytical development. While in this role, she led a cross-functional team to achieve successful completion of clinical manufacturing for a Phase 3 clinical trial for NeoCart®, an autologous tissue-engineered cartilage product. Prior to Histogenics, Caroline spent thirteen years at Genzyme Corporation in manufacturing technical support and compliance leadership roles. She initially focused on biomanufacturing and technology for Genzyme’s core enzyme replacement therapy products, Cerezyme®, Fabrazyme®, and Myozyme®. She supported commercial manufacturing operations by analyzing process performance, addressing production issues, and implementing process improvements. She later transitioned into a quality compliance role in which she made critical contributions to addressing quality system challenges. She led teams through design, implementation, and operation of remediated quality systems to enable successful completion of Genzyme’s work plan to improve quality systems at its Allston Landing Facility.

Caroline has a BSE in chemical engineering and a MS in biomedical engineering from the University of Michigan.

Kimya Harris, PhD, Head of Intellectual Property

Kimya Harris is a skilled intellectual property professional with significant oncology patent experience both within the biopharmaceutical industry and in private practice. Prior to joining KSQ Therapeutics, Kimya held several roles of increasing responsibility during her six year tenure at ImmunoGen, most recently, as Senior Director, Intellectual Property. In this role, Kimya was responsible for ImmunoGen’s extensive patent portfolio for its antibody drug conjugate technology, including the development and execution of global IP strategies. Kimya’s work at ImmunoGen also included due diligence and competitive intelligence assessment for research and development product candidates and IP collaboration management in the negotiation and development of strategic partnerships. Prior to joining ImmunoGen, Kimya spent 10 years at Clark + Elbing, LLP, a boutique IP law firm, managing complex patent portfolios for leading biotechnology and pharmaceutical companies and academic institutions.

Kimya earned her PhD in Molecular Biology from the University of Michigan, where her research focused on cell cycle regulation. She continued her research in cancer biology as a postdoctoral fellow at Harvard Medical School before pursuing her career in patent law.

René M. Lemieux, PhD, Head of Chemistry and Drug Design

René Lemieux is an experienced and successful drug hunter with nearly 20 years of experience in large pharma and biotech bringing first-in-class small molecule drug candidates from discovery to clinical trials. Prior to joining KSQ Therapeutics, René served as Director of Medicinal Chemistry at Agios Pharmaceuticals where he was responsible for leading the discovery efforts for a number of programs in the area of cancer metabolism and rare genetic diseases. During his tenure at Agios, René was a primary contributor to the discovery of AG-120, the first-in-class inhibitor of the IDH1 mutant enzyme, which is currently being evaluated in patients with cancers harboring an IDH1 mutation. Before Agios, he spent 13 years at Boehringer Ingelheim Pharmaceuticals where he held scientific and leadership roles with increasing responsibility and was the recipient of the BI’s President’s Award for his work on an LFA-1 antagonism drug discovery program.

René earned his PhD in Chemistry at the University of British Columbia and completed a post-doctoral research fellowship in Chemistry with Professor Albert I. Meyers at Colorado State University. He is co-inventor of numerous patent applications and co-inventor of seventeen issued US patents in addition to having published several peer-reviewed articles in top tier journals.

Hanlan Liu, PhD, MBA, Head of Non-clinical Drug Metabolism and Pharmacokinetics

Hanlan Liu has broad experience and a deep understanding of pharmaceutical R&D process based on more than 20 years of drug metabolism and pharmacokinetics responsibilities in pharmaceutical and biotech organizations. Prior to joining KSQ Therapeutics, Hanlan served as Executive Director and Head of DMPK and Clinical Pharmacology at Catabasis Pharmaceuticals where she led the non-clinical strategy and work plan for edasalonexent, an NF-B inhibitor for Duchenne Muscular Dystrophy, as well as the DMPK strategy and work plan for the IND filing of CAT-5571, a novel therapy for the treatment of patients with cystic fibrosis. Prior to Catabasis, Hanlan spent 14 years at Genzyme and then Sanofi with increasing responsibilities, resulting in her promotion to Senior Director in DMPK. During her tenure at Genzyme and Sanofi, Hanlan built and led multiple collaborative and science-driven pharmaceutics function groups associated with more than 30 drug discovery projects in multiple disease areas, several of which advanced to clinical trials. She contributed to five IND filings and several product submissions and/or post market drug life cycle dossiers, including those for Hectorol®, Mozobil®, Mipomerson® and Cerdelga®. Hanlan began her career at Ostuka in analytical and formulation roles and then Wyeth-Ayerst Research in early drug discovery.

Hanlan earned her PhD of Analytical Medicinal Chemistry and Molecular Pharmacology and conducted postdoctoral work at Purdue University, prior to completing her MBA in Corporate Finance with distinction at New York University. Hanlan graduated with a BS in Biochemistry with honor at Wuhan University. Hanlan is the co-inventor on four patents including C.O.M. for Cerdelga® and venglustat, and she is co-author of 31 peer-reviewed scientific publications.

Douglas Pagán, Chief Financial Officer

Doug Pagán brings more than 25 years of financial and operational experience in the biopharmaceutical industry. Prior to joining KSQ, Mr. Pagán was Chief Financial Officer of Paratek Pharmaceuticals, where he played a key role in transforming Paratek from a development stage company to a commercial company, and had responsibility for finance, investor relations, strategic planning and SEC reporting. Under his financial leadership, Paratek raised more than $450 million in equity financing and maintained a strong balance sheet to support the commercialization of the company’s first antibiotic product.

Prior to Paratek, Mr. Pagán served as Vice President, Finance at Acceleron Pharma Inc., where he was responsible for strategic and financial planning, accounting, SEC reporting, treasury and financial operations, and played a significant role in the company’s Initial Public Offering. Prior to working at Acceleron, he served in strategic and financial management roles at Biogen Idec and Bristol-Myers Squibb. Previously, Mr. Pagán worked in healthcare investment banking at J.P. Morgan, as well as pharmaceutical operational roles at Johnson & Johnson. Mr. Pagán received his BSE in Chemical Engineering from Princeton University and his MBA from Columbia Business School.

Frank Stegmeier, PhD, Chief Scientific Officer

Frank Stegmeier is an industry-leading expert in genetics, cancer biology and functional genomics who has led the industrialized application of functional genomics for oncology drug discovery in the pharmaceutical industry. Prior to joining KSQ Therapeutics, Frank served as Director and Head of Global Oncology Target Discovery at the Novartis Institutes for Biomedical Research (NIBR), where he was responsible for developing the early oncology drug discovery portfolio. Frank also led the therapeutic siRNA research strategy at Novartis and directed the Cancer Cell Line Encyclopedia collaboration with the Broad institute. During his tenure at Novartis, Frank and his team identified more than a dozen novel oncology targets and advanced multiple chemical entities addressing these targets into preclinical development. He also led the biology efforts to advance the PKC inhibitor Sotrastaurin into phase I clinical trials in lymphomas and uveal melanoma. Frank was awarded the prestigious Novartis VIVA Leading Scientist Award for his vision, scientific excellence and innovative leadership.

Frank earned his PhD in biology from MIT and was a Helen Hay Whitney postdoctoral fellow at Harvard Medical School in Dr. Stephen Elledge’s lab. He has authored numerous patents and published in top-tier scientific journals including Cell, Nature, Science, and Nature Medicine.

John Trzupek, MBA, PhD, Chief Business Officer

John Trzupek is an accomplished leader in the biotech and pharmaceutical industries with key contributions spanning drug discovery, strategy, operations, and entrepreneurship. Prior to joining KSQ Therapeutics, John held several business and scientific roles at Pfizer. Most recently, he served as Director of Strategy, Inflammation & Immunology where he founded and led a highly successful interdisciplinary drug discovery unit and also seeded investment in new diseases and research areas. In his prior work as a scientist at Pfizer, John was the co-inventor of multiple product candidates that reached the clinic. Notably, he was a primary contributor to the design and discovery of PF-06650833, a novel small molecule inhibitor being studied for the treatment of autoimmune disease. He also helped to pioneer and build a successful open innovation collaboration with the Structural Genomics Consortium that has resulted in the generation of multiple publicly-available, highly selective, and high quality chemical probes for epigenetic targets.

John earned an MBA with high honors as an Amy and Richard F. Wallman Scholar from the University of Chicago Booth School of Business where he concentrated in Finance. He also earned his PhD in organic chemistry from The Scripps Research Institute as a National Defense Science and Engineering (NDSEG) Predoctoral Fellow and completed his postdoctoral training at Memorial Sloan-Kettering Cancer Center.

Ben B. Wolf, MD, PhD, Chief Medical Officer

Ben Wolf brings nearly 20 years of experience in the biopharmaceutical industry as a senior clinical leader in oncology drug development, with expertise advancing new oncology programs in the clinic and optimizing patient selection to enable rapid proof of concept and registration.

Prior to joining KSQ, Dr. Wolf was Senior Vice President, Clinical Development at Blueprint Medicines, where he advanced three oncology programs for novel kinase inhibitors from investigational new drug (IND) applications to clinical proof-of-concept. During his four-year tenure, the clinical progress on Blueprint’s pipeline of oncology programs resulted in three breakthrough designations, plenary presentations for three different clinical programs at major oncology meetings, multiple publications in high-impact peer-reviewed cancer journals, and a range of other data presentations to the oncology and biotechnology communities.  Dr. Wolf also played a leadership role in the global registration strategies for these kinase inhibitor programs.

Previously, Dr. Wolf served as Senior Medical Director for Merrimack Pharmaceuticals where he advanced preclinical, translational and clinical development of a novel cancer antibody, leading all aspects of drug development, biomarker/companion diagnostic development, clinical planning, publications and patent submissions. Prior to working at Merrimack, he served in clinical and medical director roles at ImmunoGen, Amgen and Genentech.  Dr. Wolf started his industry career as a discovery scientist at Genentech. He earned a BS from Union College.  Dr. Wolf received his MD and PhD (Biochemistry) from the University of Virginia, and board certification in Internal Medicine and Medical Oncology after completing medical training at the University of California at San Diego.  He has authored more than 30 peer-reviewed publications and multiple patents related to drug discoveries.

Andrew Wylie, PhD, Head of Discovery Biology

Andrew Wylie has over 16 years of oncology drug discovery experience in both small biotech and big pharma environments. Prior to joining KSQ Therapeutics, Andrew served as a Director in the Oncology group at the Novartis Institutes for BioMedical Research where he was responsible for leading drug discovery teams from early conceptual stages to the nomination of clinical candidates. In this role, Andrew led internal and external teams that identified and progressed a number of important oncology programs from lead optimization through IND-enabling studies including Asciminib (ABL001), the first allosteric inhibitor targeting BCR-ABL and LXS196 a PKC inhibitor in development for uveal melanoma. Prior to joining Novartis, Andrew held oncology drug discovery roles of increasing responsibility at Infinity Pharmaceuticals and Vertex. Andrew earned his PhD in Genetics from the University of Glasgow, Scotland, and was an AstraZeneca postdoctoral fellow based in Duke University, North Carolina, USA. He has authored several patents and published in top-tier scientific journals.

Scientific Founders

David Sabatini, MD, PhD, Founder

Dr. David M. Sabatini is one of the most respected leaders in the field of molecular cell biology, and has spent his career delving deeply into the mechanisms that regulate cell growth. He is a Member of the Whitehead Institute for Biomedical Research, Professor of Biology at the Massachusetts Institute of Technology, and an Investigator of the Howard Hughes Medical Institute. He is also a Senior Associate Member at The Broad Institute MIT and Member of the Koch Institute for Integrative Cancer Research at MIT. A longtime interest of his research is the signaling pathway anchored by the mTOR kinase, which David discovered when he was an MD/PhD student at Johns Hopkins Medical School. The mTOR signaling network is a central regulator of growth, metabolism, and aging; the target of the well-known drug rapamycin; and is deregulated in common diseases, including cancer and diabetes. David’s lab is also a leader in developing new technologies such as cell-based microarrays for high throughput screening of cDNAs, and genome-scale RNAi and CRISPR/Cas9 libraries that can be applied to diverse biological problems. David has received a number of distinctions, including being named a W. M. Keck Foundation Distinguished Young Scholar, a Pew Scholar, a TR100 Innovator, a recipient of the 2009 Paul Marks Prize for Cancer Research, 2012 The Earl and Thressa Stadtman Scholar Award from ASBMB, 2013 Feodor Lynen Award from Nature, the 2014 NAS Award in Molecular Biology, and the 2014 Colin Thomson Memorial Medal. In 2016, David was elected into the National Academy of Sciences.

David received his BS from Brown University magna cum laude and his MD/PhD from Johns Hopkins University in 1997. He completed his thesis work in the lab of Dr. Solomon H. Snyder in the Department of Neuroscience.

Jonathan Weissman, PhD, Founder

Dr. Jonathan Weissman is widely recognized for building innovative tools for broadly interrogating the organizational principals of biological systems. These include ribosome profiling for globally monitoring protein translation and the development of CRISRPi/a to enable fine-tuned modulating human gene expression at genome scale. He is Professor of Cellular & Molecular Pharmacology at the University of California, San Francisco and an Investigator of the Howard Hughes Medical Institute. He has received the Raymond and Beverly Sackler International Prize in Biophysics, the National Academy of Sciences Award for Scientific Discovery, the Keith R. Porter Lecture Award from the American Society for Cell Biology (2015) and the Irving Sigal Young Investigator Award from the Protein Society (2004). Dr. Weissman is a member of the National Academy of Sciences.

Dr. Weissman received his undergraduate physics degree from Harvard College. After obtaining a PhD in physics from the Massachusetts Institute of Technology, where he worked with Peter Kim, Dr. Weissman pursued postdoctoral fellowship training in Arthur Horwich’s laboratory at Yale University School of Medicine.

William Hahn, MD, PhD, Founder

Dr. William C. Hahn is a physician-scientist involved both the care of cancer patients and biomedical research directed toward a greater understanding of the mechanisms involved in malignant transformation. Dr. Hahn is a medical oncologist and Professor in the Department of Medical Oncology and an Institute Member of the Broad Institute of MIT and Harvard. He co-directs the Center for Cancer Genome Discovery, is the Chief of the Division of Molecular and Cellular Oncology and is the Chair of the Executive Committee for Research at the Dana-Farber Cancer Institute. Using genome scale tools and approaches, his laboratory is focused on the discovery of new targets and combination therapies for pancreatic, colon, breast and prostate cancer. Dr. Hahn has served as the President of the American Society for Clinical Investigation and has been elected to the Association of American Physicians. He has been the recipient of many honors and awards including the Wilson S. Stone Award from M.D. Anderson Cancer Center for outstanding research in cancer (2000), a Howard Temin Award from the National Cancer Institute (2001), the Ho-Am Prize in Medicine (2010) and the Richard and Hinda Rosenthal Award from AACR (2015).

Dr. Hahn received his MD and PhD from Harvard Medical School in 1994. He then completed clinical training in internal medicine at Massachusetts General Hospital and medical oncology at DFCI. He conducted his postdoctoral studies with Dr. Robert Weinberg at the Whitehead Institute and joined the faculty of DFCI and Harvard Medical School in 2001.

Tim Wang, PhD, Founder

Tim Wang has pioneered the development of a novel method for conducting genome-wide genetic screens in human cells using the CRISPR/Cas9 system. He is a PhD student in the Department of Biology at MIT conducting his thesis research in the laboratories of David Sabatini and Eric Lander. Using the CRISPR/Cas9 approach, he has identified the set of genes required for proliferation in a human cancer cell line; his seminal work was published in two Science papers in 2014 and 2105. By extending this approach across a large collection of cancers, it will be possible to pinpoint highly specific vulnerabilities which may be exploited for the development of targeted cancer therapies.

Tim received a BS in bioengineering from the University of California, Berkeley and a PhD in biology from the Massachusetts Institute of Technology. He is a recipient of the NSF Graduate Research Fellowship, the NIH Ruth L. Kirschstein National Research Service Award, the 2016 Harold M. Weintraub Graduate Student Award, and the 2017 Forbes 30 Under 30 Award in Healthcare. He is currently conducting postdoctoral studies at the Janelia Research Campus.

Board of Directors

Jim Gilbert, MBA, Chairman of the Board

Jim Gilbert is Senior Partner at Flagship Pioneering. He joined Flagship in 2016, bringing to the firm more than 35 years of experience in business strategy for life sciences and healthcare companies. At Flagship, Jim participates in corporate innovation partnerships and investments for the nutritional health sector of the firm. He is also involved with strategic planning for the broader Flagship organization.

Jim began his career at Bain & Company, where he stayed for over 24 years. Based in Boston and Munich, Jim served as the managing director of Bain’s Global Healthcare Practice, with a focus on serving medical technology, biopharmaceuticals, and life science tools clients. He also held the position of chairman of the management committee. As a leading member of Global Strategy Practice at Bain, Jim was a published author and speaker, sharing insights on medical technology and pharmaceutical industry strategic trends and issues as well as “profit pool-based” and “strategic principled-based” strategy implementation.

After Bain, Jim joined Boston Scientific as group president of the Global Cardiovascular Group and executive vice president of corporate strategy, business development, marketing, and health economics and reimbursement. Among other duties, he was responsible for providing strategic support on key projects and growth initiatives within Boston Scientific’s broad portfolio.

Most recently, Jim worked as an investor, board member, and advisor in the healthcare and life sciences industry. Before joining Flagship in 2016, Jim served as a senior advisor to the investment firm, General Atlantic, and as a senior operating executive at Welsh, Carson, Anderson & Stowe. He was on the board of directors of Nestlé Health Science between 2012 and 2016. Jim is on the boards of multiple healthcare and life sciences companies, including Flagship portfolio companies TransMedics, Rubius Therapeutics, and Sigilon. Jim joined Rubius as director in 2015 and served as the company’s chairman until mid-2016. He is on the board of several other companies, including ECG Management Consultants and National Dentex Corp.

Jim graduated from Cornell University School of Engineering, where he earned a BS in industrial engineering and operations research with high distinction, and he holds an MBA with distinction from Harvard Business School.

David Meeker, MD, Chief Executive Officer

Dr. Meeker is the President & CEO of KSQ, a biotech company with a proprietary CRISPRomics drug discovery engine. Utilizing this engine, KSQ is advancing a pipeline of oncology and immuno-oncology drug development programs. Dr. Meeker was formerly the President and CEO of Genzyme, a Sanofi company, a position he assumed when Genzyme merged with Sanofi in 2011. He was also a member of the executive committee.

In his career with Genzyme, Dr. Meeker held key positions of increasing responsibility beginning in the R&D organization and subsequently in operating roles, culminating in the position of Chief Operating Officer at the time of the merger. In his most recent role within Sanofi, he headed Sanofi-Genzyme, the specialty care unit with responsibility for Rare Diseases, MS, Oncology and Immunology franchises.

Prior to joining Genzyme, Dr. Meeker was the Director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic and an assistant professor of medicine at Ohio State University. He completed his internal medicine training at Harvard’s Beth Israel Hospital and his pulmonary/critical training at Boston University. He completed the Advanced Management Program at Harvard Business School in 2000.

Dr. Meeker is the Chairman of the Board of Rhythm Pharmaceuticals, and Trevi Therapeutics and a member of the board at Myokardia. He also serves on the boards of the Biomedical Science Careers Program, the Network for Excellence in Health Innovation and the Dimock Center, a Boston based community health center.

Alan Crane, MBA, Board Member

Alan Crane is a Partner and Entrepreneur at Polaris Partners focusing on building and investing in healthcare companies. He has served as founder and/or has played a significant role as chairman and CEO in building six Polaris companies including: Momenta Pharmaceuticals (NASDAQ: MNTA), Cerulean Pharma (NASDAQ:CERU), Visterra, Navitor Pharmaceuticals, XTuit Pharmaceuticals and Arsia Therapeutics. In addition, he currently serves on the board of Seventh Sense Biosystems and has previously represented Polaris on the boards of T2 Biosystems (NASDAQ: TTOO), Ocular Therapeutix (NASDAQ: OCUL), Sirtris Pharmaceuticals (NASDAQ: SIRT, acquired by Glaxo SmithKline) and Adnexus Therapeutics (acquired by Bristol Myers Squibb).

From 2002 to 2006, Alan was President and CEO of Momenta Pharmaceuticals (NASDAQ: MNTA). He joined Momenta as the fifth employee and built it into a public company, creating an advanced and diversified pipeline, entering into two strategic collaborations with Novartis and raising $275 million. The first product from Momenta’s pipeline achieved over $1B during its first year of sales.

Prior to Polaris, Alan was Senior Vice President of Global Corporate Development at Millennium Pharmaceuticals, where he was responsible for leading Millennium’s strategic partnering, mergers and acquisitions, and licensing activities, generating over $2B in partner funding and acquiring 19 development stage products. Among these products was Velcade which became the main basis of the company’s $9B acquisition by Takeda. Before joining Millennium, Alan was a marketing executive at DuPont-Merck and a consultant with the Boston Consulting Group and Arthur D. Little.

Alan earned a BA in Biology, summa cum laude, from Harvard College, an MA in Cellular and Developmental Biology from Harvard Graduate School of Arts & Sciences and an MBA, with honors, from Harvard Business School. He also spent two years studying towards an MD at Harvard Medical School.

George Golumbeski, PhD, Board Member

Trained as a research scientist (Doctorate in Genetics), George has become a leader at enabling young, innovation-driven companies that seek to bring breakthrough medications to patients suffering from cancer and/or chronic inflammation. In his 25+ years in this sector, George has held senior positions in R&D and business development. He has worked on many medications that have reached the market and are benefiting patients worldwide, and he is known globally in the biotechnology industry for his interest in leading-edge science and his innovative approaches to forging inter-company collaborations. George was most recently Executive Vice President of Business Development for Celgene Corporation, where he was responsible for the full array of worldwide business development activities including evaluation of opportunities, structuring and negotiating collaborations, mergers and acquisitions, and alliance management.

George earned a BA in Biology from the University of Virginia and a PhD in Genetics from the University of Wisconsin-Madison. George has served on the Board of Directors of multiple biotechnology companies.

Richard Moscicki, MD, Board Member

Richard Moscicki has more than 25 years of leadership experience in translational medicine, clinical development, regulatory affairs and medical affairs in the pharmaceutical industry.

Rich is currently the Executive Vice President for Science and Regulatory Advocacy and the Chief Medical Officer at Pharmaceutical Research and Manufacturers of America (PhRMA). From 2013 to 2017, prior to joining PhRMA, he served as the Deputy Center Director for Science Operations for the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER). Rich was senior vice president and head of Clinical Development at Sanofi-Genzyme from 2011-2013. He was Chief Medical Officer at Genzyme Corporation from 1992 to 2011, where he was responsible for worldwide global regulatory and pharmacovigilance, as well as all aspects of clinical research and medical affairs.

Rich is board certified in internal medicine, diagnostic and laboratory immunology, and allergy and immunology. He completed his residency in internal medicine, followed by a fellowship at Massachusetts General Hospital in clinical immunology and immunopathology. He remained on staff at MGH and on the faculty of Harvard Medical School from 1979 until 2013. Rich received his medical degree from Northwestern University Medical School.

Pearl Huang, PhD, Board Member

Pearl Huang is the President and Chief Executive Officer of Cygnal Therapeutics, a Flagship Pioneering company. She is also on the board of Cygnal and a venture partner at Flagship Pioneering.

Before joining Cygnal, Pearl most recently served as Senior Vice President and Global Head of tTherapeutic Modalities at Roche, where she oversaw the discovery of biologic, small molecule, and nucleic acid-based therapies. Prior to Roche, Pearl was Vice President and Global Head of Discovery Academic Partnerships at GSK. In 2010, she founded BeiGene and served as Chief Scientific Officer until 2012, developing the company’s initial drug discovery pipeline and moving the company’s first programs into the clinic. From 2006 to 2010, Pearl served as Vice President, Oncology Integrator, Discovery and Early Development at Merck, leading 14 early development teams and conducting seven first-in-human trials in one year. Prior to that, she led oncology discovery at GSK, initiating the programs that delivered tramentinib and dabrafenib to patients.

Pearl received her undergraduate degree in life sciences from the Massachusetts Institute of Technology and a Ph.D. in molecular biology from Princeton University.

Theo Melas-Kyriazi, MBA, Board Member

Theo Melas-Kyriazi joined Flagship Pioneering as an Executive Partner in April 2019. Prior to joining the firm, Theo served as chief financial officer of Levitronix Technologies, a worldwide leader in magnetically levitated bearingless motor technology. Before Levitronix, Theo held a nearly two-decade career at Thermo Fisher Scientific, where he served in a variety of roles including Treasurer, CFO, and CEO of a publicly-traded Thermo subsidiary where he increased revenues from $40M to $200M over 4 years.  As Treasurer and then CFO, Theo was instrumental in raising $2B in equity and convertible debt; executing 5 IPOs of Thermo subsidiary companies; and executing a broad restructuring that transformed Thermo from $4B revenue diversified holding company into a $2B company focused on serving life science customers.

Over the last 20 years, Theo has served on the boards of multiple public and private healthcare and life science companies, including Moderna, Valeant Pharmaceuticals, Thoratec Corporation, Helicos Biosciences, and Evelo Biosciences.  He also served as an operating partner of a middle-market private equity firm from 2007 to 2012.

Theo holds a bachelor’s degree in economics and an MBA from Harvard University.